Form 4: Deerfield Funds Significantly Increase Larimar Stake

Deerfield Management and affiliated funds have significantly increased their beneficial ownership in Larimar Therapeutics by purchasing common stock at $3.2 per share on July 31, 2025.

Summary

• James E. Flynn, a Director and 10% Owner of Larimar Therapeutics, along with several Deerfield Management affiliated funds, reported acquisitions of Larimar Therapeutics common stock.
• The transactions occurred on July 31, 2025.
• Shares were acquired at a price of $3.2 per share.
• Deerfield Private Design Fund III, L.P. acquired 3,387,529 shares, increasing its beneficial ownership to 9,538,918 shares.
• Deerfield Private Design Fund IV, L.P. acquired 3,387,539 shares, increasing its beneficial ownership to 9,538,945 shares.
• Deerfield Healthcare Innovations Fund, L.P. acquired 2,599,932 shares, increasing its beneficial ownership to 7,321,129 shares.
• Deerfield Partners, L.P. beneficially owns 4,207,982 shares.
• The reporting persons collectively hold significant beneficial ownership, with James E. Flynn and the Deerfield entities identified as Directors, 10% Owners, and 'Director by Deputization'.

Sentiment

Score: 9

Explanation: The significant investment by a major healthcare-focused institutional investor like Deerfield Management, coupled with their existing board representation, signals strong confidence in Larimar Therapeutics. The fixed purchase price provides a clear valuation point. This is a very positive insider buying signal.

Positives

• Significant investment by a major institutional investor (Deerfield Management) and its affiliates, indicating strong confidence in Larimar Therapeutics.
• The fixed purchase price of $3.2 per share provides a clear valuation point for this transaction.
• Increased alignment of interests between a major shareholder group and the company's future performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-arranged, systematic approach to share acquisition.

Future Outlook

Deerfield Management and its affiliated funds have significantly increased their stake in Larimar Therapeutics through a pre-arranged purchase of common stock at $3.2 per share on July 31, 2025, signaling a long-term commitment and positive outlook from a major institutional investor.

Management Comments

• This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the 'Reporting Persons').
• For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
• Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer.

Industry Context

This significant investment by Deerfield Management, a prominent healthcare-focused investment firm, suggests a positive long-term view on Larimar Therapeutics within the biotechnology and pharmaceutical sector. Such an investment by a specialized fund often indicates confidence in the company's pipeline, clinical progress, or market potential, potentially setting a positive precedent for other investors in the industry.

Comparison to Industry Standards

• While specific comparable transactions are not detailed, large-scale insider purchases by institutional investors like Deerfield Management are generally viewed favorably, similar to how major pharmaceutical companies or venture capital firms make strategic investments in promising biotech firms.
• The fixed price of $3.2 per share provides a benchmark for this specific transaction, which can be compared to recent trading prices of LRMR and valuations of other clinical-stage biotechnology companies, though the filing does not provide such comparative data.
• The involvement of a 'Director by Deputization' and a 10% owner group (Deerfield) is a common structure for significant institutional investors to exert influence and oversight, aligning with corporate governance practices seen in other biotech investments where major shareholders take board seats.

Related Party Transactions

• The transactions involve James E. Flynn, a Director and 10% Owner, and Deerfield Management entities, which are also 10% owners and have a director (Jonathan S. Leff) on Larimar's board, indicating related party dealings.
• The acquisitions are by funds managed by Deerfield Management, where James E. Flynn is the sole manager of the general partners of the managing entities, establishing a clear related party relationship.

Stakeholder Impact

• Shareholders: The significant investment by a major institutional holder could be perceived positively, potentially boosting investor confidence and signaling a floor for the stock price at the transaction level of $3.2 per share. It also increases the concentration of ownership.
• Company (Larimar Therapeutics): If these are newly issued shares, it represents a capital infusion. If from the open market, it signifies strong demand from a key investor. In either case, it strengthens the company's investor base and potentially its financial stability.

Next Steps

• Observe any subsequent Form 4 filings related to these transactions or further changes in beneficial ownership by Deerfield.

Key Dates

Recommendation

The substantial purchase of Larimar Therapeutics common stock by Deerfield Management and its affiliated funds, including a director and 10% owner, at a fixed price of $3.2 per share, represents a very strong vote of confidence from a sophisticated institutional investor. This insider buying, especially of this magnitude, suggests that those closest to the company and with deep industry knowledge believe the stock is undervalued or has significant upside potential. This aligns interests and provides a strong positive signal for other investors, warranting a 'strong buy' recommendation based on this filing.

Keywords

Larimar Therapeutics, LRMR, Deerfield Management, Insider Trading, Form 4, Stock Purchase, Biotechnology, Pharmaceuticals, Investment, Beneficial Ownership